Da Volterra

#ESMO22: Don’t miss Dr. Messaoudene‘s (@CRCHUM, Montreal) mini oral presentation on Sunday 11.09 at 15:25 CET (1663MO): key preclinical results showing the importance of DAV132 in #immunooncology will be presented davolterra.com/2022/09/08/da-… #cancer #immunotherapy #microbiome

This article in @Nature highlights the importance of the #microbiome in response to #cancer treatment: “Long-term responders had a more diverse tumour microbiome than did those who survived less than five years”! nature.com/articles/d4158…

This Wednesday, Jean De Gunzburg, CSO of Da Volterra, will speak at the 8th Annual Microbiome Connect Europe 2022 on Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy, on July 6th, at 11.30am CET. Don’t miss it! davolterra.com/2022/07/05/jea… @KR_Microbiome

Happy 2022 World Microbiome Day! @DaVolterra, we are developing gut microbiome-protective therapies and we believe that preserving the #microbiome of #cancer patients is critical to their treatment response and survival. davolterra.com/wp-content/upl… @WMicrobiomeDay

Da Volterra's CSO, Jean de Gunzburg, is attending the 7th Microbiome Movement Drug Development Summit on June 21-24 in Boston, the most comprehensive forum for microbiome drug developers. microbiome-summit.com @MicrobiomeDaily #microbiome #MicrobiomeMovement #oncology #Biotech

These June 13-16, Da Volterra’s BD Manager, Julie Cervesi, will be at BIO 2022 in San Diego with exciting news to share during the world’s largest leading biotech convention. Looking forward to meeting potential partners! davolterra.com/2022/05/24/da-… #BIO2022 #Microbiome #Cancer

Don’t miss Da Volterra’s BD Manager, Julie Cervesi, poster presentation on 'Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with ICIs’ at ASCO on June 5, 8:00-11:00 AM CDT meetings.asco.org/abstracts-pres…

Meet with us at BIO 2022 in San Diego, June 13-16! Find Da Volterra in the partnering system for potential meetings at the largest gathering of the global biotech community! login.partnering.bio.org/inova-business… @businessfrance

Da Volterra will participate to ASCO Annual Meeting in Chicago and present a poster: ‘Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitor’ davolterra.com/2022/05/23/da-…

Da Volterra delighted to announce positive preclinical results in immuno-oncology with DAV132, a revolutionary gut protector davolterra.com/2022/04/28/pos… #Biotech #Immunotherapy #Microbiome #Cancer

Don’t miss Dr Routy’s presentation @AACR on April 11 at 8pm CET: he will present non-clinical results showing the crucial role of the gut microbiome on response to anti-PD-1 and the ability of DAV132 to maintain the full efficacy of anti-PD-1 by protecting the @microbiome!

Exciting new science in @NatureMedicine for CAR-T patients, perturbations in the intestinal #Microbiome are associated with lower survival and increased neurotoxicity after CAR-T cell therapy in patients with B cell malignancies. doi.org/10.1038/s41591… #Cancer

Don’t miss the presentation of Jean de Gunzburg, Da Volterra's CSO, on preserving the intestinal microbiome from antibiotic-induced dysbiosis with DAV132, an effective & safe solution for #cancer patients during last PRI Annual Event in @MicrobiomeTimes. microbiometimes.com/biotech-showca…

The whole @DaVolterra team is supporting #WorldCancerDay to reimagine a world where millions of cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all! worldcancerday.org #CloseTheCareGap

We welcome 2022 as a new challenge to learn from past mistakes and fight #AMR. Read our reflection paper on PULL incentives which explains why a hybrid Transferable Exclusivity Extension & Subscription model would be a solution for the #EU27 to consider. bit.ly/3AKLpzn

The first comprehensive analysis of the global impact of AMR estimates resistance itself caused 1.27 million deaths in 2019. A shocking leap from previous estimates of 700k deaths a year. It is clear - AMR is one of the greatest threats to public health. bit.ly/3rxoQKt

New OA Publication @BSACandJAC showing #DAV132 preserved intestinal #microbiota diversity and C. difficile colonization resistance: academic.oup.com/jac/advance-ar… @mjvehreschild

Da Volterra glad to announce the publication of its positive Phase 2 results in the Journal of Antimicrobial Chemotherapy: it is a considerable achievement for DAV132 and a leap towards commercialization. Read the article: academic.oup.com/jac/advance-ar… #Microbiome #Biotechs #Health

Da Volterra wishes you #HappyHolidays and a prosperous & healthy #2022! #Seasonsgreetings to you all!